2023
Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Singh S, Jangi S. Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission. Journal Of Clinical Gastroenterology 2023, 58: 195-199. PMID: 36753459, PMCID: PMC10406966, DOI: 10.1097/mcg.0000000000001834.Peer-Reviewed Original ResearchConceptsEtiology of relapseRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionDiscontinuation of therapyClinical relapseUlcerative colitisNormalization of C-reactive proteinCumulative riskRetrospective cohort studyC-reactive proteinTufts Medical CenterEndoscopic remissionHistological remissionRelapse riskIdentified etiologyRemissionRelapseCohort studyPatientsHistological changesMedical recordsColitisElectronic medical records
2022
Infliximab-Induced Non-specific Interstitial Pneumonitis in a Patient With Ulcerative Colitis (UC)
Nasir S, Patel R, Wojkiewicz S, Scatena R. Infliximab-Induced Non-specific Interstitial Pneumonitis in a Patient With Ulcerative Colitis (UC). Cureus 2022, 14: e33064. PMID: 36721597, PMCID: PMC9883057, DOI: 10.7759/cureus.33064.Peer-Reviewed Original ResearchNon-specific interstitial pneumonitisInterstitial lung diseaseInflammatory bowel diseaseTumor necrosis factorUlcerative colitisInterstitial pneumonitisAdverse effects of infliximabInfections due to immunosuppressionModerate to severe inflammatory bowel diseaseFamily of tumor necrosis factorSevere inflammatory bowel diseaseHigh dose steroidsEffect of infliximabInflammatory bowel disease patientsConnective tissue disordersDose steroidsHistological remissionInfliximab infusionLung biopsyRare complicationLung findingsPulmonary statusRespiratory statusTissue disordersAlpha inhibitorsPREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Jangi S. PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION. Inflammatory Bowel Diseases 2022, 28: s47-s48. DOI: 10.1093/ibd/izac015.073.Peer-Reviewed Original ResearchRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionHistological remissionClinical relapseUlcerative colitisDisease durationEndoscopic remissionCumulative riskMedian follow-up timeDuration of follow-upPredictive of clinical relapseMedian disease durationFollow-up timeRetrospective cohort studyPredictors of relapseMayo endoscopic scoreTufts Medical CenterPatient-reported outcomesMedian ageRelapse rateRelapse riskEndoscopic scoreElectronic medical records
2019
Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
Tran C, Abu-Sbeih H, Luo W, Lu Y, Wang Y. Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. Journal Of Immunotherapy And Precision Oncology 2019, 2: 40-45. DOI: 10.4103/jipo.jipo_18_18.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsLung cancerSteroid courseAdverse eventsAbstract Immune checkpoint inhibitorsUpper GI adverse eventsSignificant anti-tumor effectGI adverse eventsProgressive lung cancerUpper gastrointestinal injuryUpper GI toxicityAnti-tumor effectsNovel therapeutic classResolution of inflammationGI-irAEsHistologic remissionHistological remissionNivolumab treatmentVedolizumab treatmentCheckpoint inhibitorsClinical remissionGastrointestinal injuryGI toxicityPrednisone taperSevere nausea
2016
Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis
Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2016, 111: 1692. PMID: 27725645, DOI: 10.1038/ajg.2016.418.Peer-Reviewed Original ResearchConceptsRelapse/exacerbationHistological remissionEndoscopic remissionClinical remissionHistological activityClinical outcomesUlcerative colitisHistological statusClinical relapseHistological featuresLamina propriaChronic inflammatory cell infiltrateAdditional prognostic utilityHistological disease activityProportion of patientsInflammatory bowel diseaseInflammatory cell infiltrateLack of blindingImproved clinical outcomesDifferent histological featuresSpecific histological featuresRandom-effects modelFixed-effects modelDisease activityUC patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply